|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Etrasimod>> Market Analysis Reports |
Market Analysis Reports of Etrasimod |
|
Ulcerative Colitis - Pipeline Insight, 2021 ... Colitis Emerging Drugs Etrasimod: Arena Pharmaceuticals Etrasimod is a next-generation, oral ... S1P receptor activity profile. Etrasimod selectively targets S1P receptor ... Ozanimod Risankizumab Mirikizumab LT-02 Etrolizumab Etrasimod Cobitolimod AJM 300 FYB ... Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2022 ... age-related macular degeneration Etrasimod: Arena Pharmaceuticals Etrasimod is a next-generation, once ... efficacy and safety profile. Etrasimod provides systemic and local ... 045 Fingolimod transdermal Ponesimod Etrasimod CP1050 Siponimod Ozanimod Amiselimod ... Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018 SUMMARY Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G ... Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Sphingosine 1-Phosphate ... Global Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026) EXECUTIVE SUMMARY Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, ... Ulcerative Colitis Market Report by Type (Mild UC, Moderate UC, Severe UC), Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis), Molecule Type (Small Molecules, Biologics), Drug Type (Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, and Others), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store, and Others), and Region 2025-2033 ... Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine ... ) adopted a positive opinion for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine ... Primary Biliary Cirrhosis - Pipeline Review, H2 2018 Primary Biliary Cirrhosis - Pipeline Review, H2 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides an overview of the Primary Biliary Cirrhosis ( ... Primary Biliary Cirrhosis - Pipeline Review, H1 2018 Primary Biliary Cirrhosis - Pipeline Review, H1 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Primary Biliary Cirrhosis ( ... Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019 This report can be delivered to the clients within 24 Hours "Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ... Ulcerative colitis - Pipeline Review, 2019 FirstView Market Insight "Ulcerative Colitis- Pipeline Review, 2019" provides an overview of the pipeline landscape for Ulcerative Colitis- Pipeline Review, 2019. It provides comprehensive insights of all the clinical and non-clinical therapeutics in ... Crohn’s Disease - Pipeline Insight, 2021 ... Upadacitinib Remestemcel-L Rifaximin Foralumab ABX464 Etrasimod CYTO-201 Masitinib Mocravimod Ortem ... Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030 ... acceptance for review of an NDA for etrasimod for patients having severe ulcerative ... Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, ... Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Drugs In Development, 2022, ... Alopecia Areata Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major alopecia areata markets are expected to exhibit a CAGR of 6.05% during 2024-2034. The alopecia areata market has been comprehensively analyzed in IMARC's new report titled "Alopecia Areata Market: Epidemiology, Industry Trends, Share, Size, ... Crohn's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major Crohn's disease markets reached a value of US$ 8,319.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11,796.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.23% during 2024-2034. The Crohn's disease market ... Hair Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major hair diseases markets reached a value of US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.6 Billion by 2034, exhibiting a growth rate (CAGR) of 6.05% during 2024-2034. The hair diseases market has been ... Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 ... acceptance for review of an NDA for etrasimod for patients having severe ulcerative ... Arena Pharmaceuticals Inc (ARNA) - Financial and Strategic SWOT Analysis Review ... company’s major product candidates include etrasimod, an oral sphingosine 1-phosphate receptor modulator ... |